Alex Leech
Partner
Works at Sofinnova
Investor profile | Builders Republic
About
Partner at Sofinnova, Alex Leech invests in pre-seed, seed, Series A, Series B, and growth with check sizes ranging from €1 to €60 million, focusing on health and life sciences, agrifood, climate, and cleantech. A partner in the Biovelocita Strategy, his track record includes Forth Therapeutics, Alchemab Therapeutics, Creabilis Therapeutics, Camphos, and Zarodex. A serial CEO, he founded Alchemab Therapeutics and served as its CEO, and he led Creabilis until its acquisition by Sienna in 2016. He has also been a Venture Partner at SV Health Investors and has experience at Pfizer R&D.
Profile
- Role
- Partner
- Fund
- Sofinnova